Various updates regarding argenx's performance and expectations have surfaced. The company is poised to report its Q3 2025 financial results and will hold an Extraordinary General Meeting of Shareholders in November 2025. Notably, the stock's potential performance in Fed rate cut cycles and during high volatility has emerged as a key focus for analysts. In addition, methods like RSI have been used to spot recovery and recommend potential entry points for investors. Citi has made a bullish move by raising the argenx's price target from $845 to $1,041. A strategic extension of the partnership between FUJIFILM Biotechnologies and argenx is expected to bolster Vyvgart production also. The biotech firm is set to present key data and innovative methodologies in immunology at the 2025 AANEM Annual Meeting. Moreover, potential risks related to argenx's stock and measures for capital preservation are outlined. The company has also received positive topline results from their ADAPT SERON. Other key updates comprise a collaboration with tennis legend Monica Seles and a $1.5B pact with Unnatural Products to explore 'undruggable' targets.
argenx News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 25 Oct 2025 23:51:47 GMT - Rating 7 - Innovation 9 - Information 8 - Rumor -5
